Ahmed O. Kaseb

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

66h-index25.9kcitations544works6.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis(265), Liver Disease Diagnosis and Treatment(114), Cancer Immunotherapy and Biomarkers(76), Cholangiocarcinoma and Gallbladder Cancer Studies(73), Colorectal Cancer Treatments and Studies(51)

Publications540 total

Utilization of immunotherapy as a neoadjuvant treatment in liver transplant recipients with hepatobiliary carcinoma.
Journal of Clinical Oncology·2026
Clinical determinants of survival and a predictive immune biomarker for immunotherapy in fibrolamellar carcinoma: A comprehensive institutional analysis.
Journal of Clinical Oncology·2026
Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of response
npj Systems Biology and Applications·2025Open Access
Circulating Fibroblast Growth Factor 21 (FGF21) as a Prognostic and Diagnostic Biomarker in Hepatocellular Carcinoma
Journal of Hepatocellular Carcinoma·2025Open Access
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
The Lancet Oncology·2025· 3 cited
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study
JHEP Reports·2025Open Access
Evaluating the role of preoperative serum insulin-like growth factor 1 as a predictor of survival and recurrence for patients with resectable hepatocellular carcinoma
Journal of Gastrointestinal Surgery·2025Open Access
478 Spatial omics and deep learning define an immunotherapy resistance niche in hepatocellular carcinoma
Regular and Young Investigator Award Abstracts·2025Open Access
Perioperative camrelizumab plus rivoceranib versus surgery in resectable hepatocellular carcinoma
The Lancet·2025
S2698 Circulating Fibroblast Growth Factor 21 (FGF21) as a Prognostic Biomarker in Hepatocellular Carcinoma
The American Journal of Gastroenterology·2025
Comprehensive Review of Transarterial Chemoembolization Plus Systemic Therapy in Advanced Hepatocellular Carcinoma
Journal of Gastrointestinal Cancer·2025· 2 cited
Linkage disequilibrium score regression identifies genetic correlations between hepatocellular carcinoma and clinically relevant traits
International Journal of Cancer·2025Open Access
Somatostatin Receptor 2 Overexpression in Hepatocellular Carcinoma: Implications for Cancer Biology and Therapeutic Applications
Current Oncology·2025· 2 citedOpen Access
987P Phase I study of tumor treating fields (TTFs) with cabozantinib or with nab-paclitaxel and pembrolizumab in patients with advanced solid tumors involving the abdomen or thorax
Annals of Oncology·2025
Single Center, Long Term Outcomes of Liver Transplant for Primary Liver & Biliary Cancers
American Journal of Transplantation·2025
Pre-Transplant Immunotherapy for Primary Liver Cancer: A Single-Center Experience
American Journal of Transplantation·2025
Burden-Dependent Outcomes of Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Retrospective Analysis
American Journal of Transplantation·2025
Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma
2025Open Access
178P Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
Annals of Oncology·2025
187P Neoadjuvant immunotherapy is associated with a recurrence free survival benefit versus active surveillance in patients with resected hepatocellular cancer
Annals of Oncology·2025
page 1 of 27Next →

Frequent Co-authors

Manal M. Hassan(14), Ann‐Lii Cheng(11), Shukui Qin(9), James L. Abbruzzese(9), Masatoshi Kudo(8), Milind Javle(8), Richard S. Finn(7), В. В. Бредер(7), Philippe Merle(7), Andrew X. Zhu(7), Rachna T. Shroff(7), Jean‐Nicolas Vauthey(7), Wendy Verret(6), Robert A. Wolff(6), Melanie B. Thomas(6), Steven A. Curley(6), Masafumi Ikeda(5), Peter R. Galle(5), Michel Ducreux(5), Ho Yeong Lim(5)